CTOs on the Move

Epic Pharmacy Network

www.epicrx.com

 
Formed in 1982 and headquartered in Maryland, EPIC Pharmacies is a not-for-profit buying group of hundreds of independently owned pharmacies across the country. EPIC offers a full range of programs and services while returning its net revenues to its members throughout the year, including a year-end distribution.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.epicrx.com
  • 5024 Campbell Boulevard Suite R
    Nottingham, MD USA 21236
  • Phone: 804.379.9060

Executives

Name Title Contact Details
Luke Gordon
Vice President of Network Development Profile

Similar Companies

Ascend SpecialtyRx

Ascend SpecialtyRx is a Port Washington, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nidek

NIDEK offers a wide array of equipment designed for the diagnosis and treatment of retinal diseases, glaucoma, and other vision-impairing afflictions.

Analgesic Solutions

Analgesic Solutions, LLC., founded in 2006, is a privately held consulting company and Clinical Research Organization. We are a hands-on team of experts across a variety of disciplines who consult on and conduct clinical trials aimed at bringing important new pain treatments to market. With hundreds of projects completed and ongoing collaborations with regulatory authorities, Analgesic Solutions is the premier choice for providing assistance and training to insure successful pain trials. Clients come to us when looking to develop and commercialize better treatments for pain. Our team, with Nathaniel Katz M.D., M.S., serving as our foremost expert, helps our clients bring their pain solutions to commercial reality.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.

SPI Pharma

SPI Pharma is a New Castle, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.